Dermal Toxicity Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Testing Method Type (In Vivo Testing, and In Vitro Testing ), By End User, By Region & Competition, 2021-2031F

Description

The Global Dermal Toxicity Testing Market is projected to increase from USD 2.11 Billion in 2025 to USD 3.38 Billion by 2031, expanding at a CAGR of 8.17%. This testing sector is essential for evaluating potential skin damage, such as irritation or corrosion, as well as systemic effects resulting from topical exposure, serving as a cornerstone for safety and compliance within the pharmaceutical, chemical, and cosmetic industries. Growth in this market is largely fueled by strict regulatory mandates like REACH and a rising ethical commitment to substitute animal testing with in vitro and in silico alternatives. Highlighting the scale of substances requiring evaluation, the European Chemical Industry Council (Cefic) reported that the European chemical industry achieved a turnover of €635 billion in 2024.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 2.11 Billion
Market Size 2031	USD 3.38 Billion
CAGR 2026-2031	8.17%
Fastest Growing Segment	In Vitro Testing
Largest Market	North America

Despite these growth factors, the market encounters significant obstacles related to the regulatory harmonization and scientific validation of alternative testing methodologies. While non-animal models are progressing, proving their complete equivalence to complex biological systems remains a major difficulty. This challenge potentially hinders the universal acceptance of these methods and restricts the broader expansion of the market, as demonstrating comparable efficacy to traditional models continues to be a substantial hurdle.

Market Driver

The robust growth of the global cosmetics and personal care industry acts as a major catalyst for the dermal toxicity testing market, spurred by the constant release of complex formulations and new ingredients necessitating thorough safety reviews. As consumers become increasingly vigilant about product safety, manufacturers must perform extensive dermal compatibility assessments to ensure compliance with international standards and prevent adverse reactions. This intense product development cycle drives a high demand for toxicological evaluations to ensure market readiness, a scale illustrated by Cosmetics Europe's 'Annual Report 2024', which noted that the European cosmetics and personal care sector achieved retail sales of €104 billion in 2024.

Concurrently, the market is transforming due to the swift uptake of alternative non-animal testing methods, driven by ethical considerations and regulatory updates like the FDA Modernization Act 2.0. This transition has hastened the commercialization of 3D reconstructed human epidermis models, which provide superior predictive accuracy for human skin reactions compared to animal testing. The strategic importance of these innovations is highlighted by Sartorius's agreement in April 2025 to acquire MatTek, a leader in 3D tissue models, for $80 million. Furthermore, the reliance on specialized external expertise supports the contract research sector, evidenced by Charles River Laboratories reporting $600.7 million in revenue for its Discovery and Safety Assessment segment in November 2025.

Market Challenge

A significant barrier facing the Global Dermal Toxicity Testing Market is the complex process of scientifically validating and harmonizing regulations for alternative testing methods. Establishing that non-animal models, such as in silico and in vitro techniques, can fully mimic the intricate physiological responses of complete biological systems is scientifically challenging, causing regulatory bodies to often hesitate in endorsing these new approaches. This caution creates a fragmented regulatory environment where specific tests may be approved in one region but not another, generating considerable uncertainty for service providers and clients navigating diverse compliance standards.

As a result, the absence of harmonization slows the commercial uptake of advanced alternative technologies and limits the market's revenue potential. Manufacturers encounter higher compliance costs and delayed product launches, which effectively stalls the industry's intended shift away from traditional animal-based testing. The economic implications are significant; Cosmetics Europe reported €104 billion in retail sales for the European cosmetics and personal care market in 2024, yet the lack of universally accepted, streamlined validation protocols for assessing this vast volume of products directly impedes the market's operational efficiency and growth trajectory.

Market Trends

The integration of Artificial Intelligence into Predictive Toxicology is transforming the market by shifting safety assessments from reactive, animal-based observations to proactive, data-centric predictions. This trend involves the use of machine learning algorithms to rapidly analyze extensive chemical libraries and forecast toxicity endpoints, encouraging pharmaceutical companies to utilize these platforms for de-risking early-stage assets. The commercial viability of computational toxicology is exemplified by Exscientia, which, according to an October 2024 press release regarding its collaboration with Sanofi, received $15 million in milestone payments after its AI-driven platform successfully identified lead compounds meeting complex requirements.

Simultaneously, the commercialization of Dermal Organ-on-a-Chip platforms is advancing the sector by evolving from academic prototypes to scalable, industrially robust systems. These microphysiological devices mimic the dynamic microenvironment of human skin and are gaining favor over static cell cultures for their superior ability to assess drug absorption and systemic toxicity. Significant investment is being directed toward expanding manufacturing capabilities for these technologies; for instance, CN Bio announced in April 2024 that it raised $21 million in Series B funding specifically to accelerate the commercial scaling of its PhysioMimix systems, underscoring the strong industry push toward physiologically relevant toxicological models.

Key Market Players

SGS S.A.
Covance, Inc
Bio-Rad Laboratories Inc.
Qiagen N.V.
GE Healthcare
Eurofins Scientific Inc
Merck KgaA
Thermo Fisher Scientific, Inc.
Charles River Laboratories International, Inc.
Catalent, Inc.

Report Scope

In this report, the Global Dermal Toxicity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermal Toxicity Testing Market, By Test Type

Skin Irritation Tests
Skin Sensitization Tests

Dermal Toxicity Testing Market, By Testing Method Type

In Vivo Testing (Animal-Based Tests)
In Vitro Testing (Cell-Based or Tissue-Based Tests)

Dermal Toxicity Testing Market, By End User

Pharmaceuticals industries
Cosmetics and personal care products industry
Chemical Industry
Other

Dermal Toxicity Testing Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermal Toxicity Testing Market.

Available Customizations:

Global Dermal Toxicity Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermal Toxicity Testing Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type (Skin Irritation Tests, Skin Sensitization Tests)
- 5.2.2. By Testing Method Type (In Vivo Testing (Animal-Based Tests) and In Vitro Testing (Cell-Based or Tissue-Based Tests))
- 5.2.3. By End User (Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry, Other)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Dermal Toxicity Testing Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type
- 6.2.2. By Testing Method Type
- 6.2.3. By End User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Dermal Toxicity Testing Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Test Type
    - 6.3.1.2.2. By Testing Method Type
    - 6.3.1.2.3. By End User
- 6.3.2. Canada Dermal Toxicity Testing Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Test Type
    - 6.3.2.2.2. By Testing Method Type
    - 6.3.2.2.3. By End User
- 6.3.3. Mexico Dermal Toxicity Testing Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Test Type
    - 6.3.3.2.2. By Testing Method Type
    - 6.3.3.2.3. By End User

7. Europe Dermal Toxicity Testing Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type
- 7.2.2. By Testing Method Type
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Dermal Toxicity Testing Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Test Type
    - 7.3.1.2.2. By Testing Method Type
    - 7.3.1.2.3. By End User
- 7.3.2. France Dermal Toxicity Testing Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Test Type
    - 7.3.2.2.2. By Testing Method Type
    - 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Dermal Toxicity Testing Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Test Type
    - 7.3.3.2.2. By Testing Method Type
    - 7.3.3.2.3. By End User
- 7.3.4. Italy Dermal Toxicity Testing Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Test Type
    - 7.3.4.2.2. By Testing Method Type
    - 7.3.4.2.3. By End User
- 7.3.5. Spain Dermal Toxicity Testing Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Test Type
    - 7.3.5.2.2. By Testing Method Type
    - 7.3.5.2.3. By End User

8. Asia Pacific Dermal Toxicity Testing Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type
- 8.2.2. By Testing Method Type
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Dermal Toxicity Testing Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Test Type
    - 8.3.1.2.2. By Testing Method Type
    - 8.3.1.2.3. By End User
- 8.3.2. India Dermal Toxicity Testing Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Test Type
    - 8.3.2.2.2. By Testing Method Type
    - 8.3.2.2.3. By End User
- 8.3.3. Japan Dermal Toxicity Testing Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Test Type
    - 8.3.3.2.2. By Testing Method Type
    - 8.3.3.2.3. By End User
- 8.3.4. South Korea Dermal Toxicity Testing Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Test Type
    - 8.3.4.2.2. By Testing Method Type
    - 8.3.4.2.3. By End User
- 8.3.5. Australia Dermal Toxicity Testing Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Test Type
    - 8.3.5.2.2. By Testing Method Type
    - 8.3.5.2.3. By End User

9. Middle East & Africa Dermal Toxicity Testing Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Test Type
- 9.2.2. By Testing Method Type
- 9.2.3. By End User
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Dermal Toxicity Testing Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Test Type
    - 9.3.1.2.2. By Testing Method Type
    - 9.3.1.2.3. By End User
- 9.3.2. UAE Dermal Toxicity Testing Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Test Type
    - 9.3.2.2.2. By Testing Method Type
    - 9.3.2.2.3. By End User
- 9.3.3. South Africa Dermal Toxicity Testing Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Test Type
    - 9.3.3.2.2. By Testing Method Type
    - 9.3.3.2.3. By End User

10. South America Dermal Toxicity Testing Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Test Type
- 10.2.2. By Testing Method Type
- 10.2.3. By End User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Dermal Toxicity Testing Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Test Type
    - 10.3.1.2.2. By Testing Method Type
    - 10.3.1.2.3. By End User
- 10.3.2. Colombia Dermal Toxicity Testing Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Test Type
    - 10.3.2.2.2. By Testing Method Type
    - 10.3.2.2.3. By End User
- 10.3.3. Argentina Dermal Toxicity Testing Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Test Type
    - 10.3.3.2.2. By Testing Method Type
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Dermal Toxicity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. SGS S.A.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Covance, Inc
15.3. Bio-Rad Laboratories Inc.
15.4. Qiagen N.V.
15.5. GE Healthcare
15.6. Eurofins Scientific Inc
15.7. Merck KgaA
15.8. Thermo Fisher Scientific, Inc.
15.9. Charles River Laboratories International, Inc.
15.10. Catalent, Inc.